Clinical trials
HER2 + Breast Cancer clinical trials
Below are recruiting her2 + breast cancer clinical trials, each written for real people, not researchers. We’re tracking 952 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06830382Recruiting
HER2-PET scan for metastatic breast cancer treatment
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
SolnaAges 18 years+ - NCT06833502RecruitingPhase 2
Screening for breast cancer spread after chemo and surgery
This trial aims to find out if doing special scans to check for breast cancer spread to organs (not just lymph nodes) is helpful in certain patients. The study looks at people with breast cancer that had already spread to lymph nodes and did not completely go away with chemotherapy and surgery.
Tampa, FloridaAges 18 years+ - NCT06828588RecruitingEarly Phase 1
A new imaging test for people on HER2 cancer therapy
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Nashville, TennesseeAges 18 years+ - NCT06806930RecruitingPhase 2
Predicting response to hormone therapy before breast cancer surgery
This trial tests whether we can predict how well hormone therapy works before surgery for early-stage breast cancer. It may help women with estrogen receptor-positive, HER2-negative or HER2-low breast cancer avoid or tailor treatments.
Washington D.C., District of ColumbiaAges 21 years+ - NCT06807749Recruiting
Adjuvant treatment for premenopausal breast cancer
This trial looks back at premenopausal women with early-stage, hormone-positive, HER2-negative breast cancer who had surgery and an Oncotype DX test, to see how different treatments affected their outcomes. If you fit this group, your past medical records could help researchers learn more about the best treatments.
Roma, Antonella PalazzoAges Up to 60 years - NCT06802172Recruiting
Timing meals during cancer treatment for Alaska Native patients
This study tests whether scheduling meals at specific times of day can improve how patients feel during cancer treatment. It is for Alaska Native or American Indian people with certain cancers (rectal, HER2+ or triple negative breast, or other solid tumors) who are receiving neoadjuvant (before surgery) or adjuvant (after surgery) therapy.
Anchorage, AlaskaAges 21 years+ - NCT06784193RecruitingPhase 1
Study of OP-3136 for advanced solid tumors
This trial tests a new drug, OP-3136, alone or with other drugs, for people with advanced breast cancer, prostate cancer, or lung cancer that has stopped responding to other treatments. It aims to see if OP-3136 is safe and effective.
Gilbert, ArizonaAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT06784921Recruiting
Study of sacituzumab govitecan for HER2-negative breast cancer
This study looks at how well a drug called sacituzumab govitecan works and how safe it is for people with a certain type of breast cancer that has spread (HER2-negative metastatic breast cancer). It aims to understand real-world results for patients in China.
Hangzhou, ZhejiangAges 18–75 - NCT06787339RecruitingPhase 2
Capecitabine for low-risk triple negative breast cancer
This trial tests whether a chemotherapy pill called capecitabine can help people with low-risk triple negative breast cancer after surgery. It is for patients with stage I disease who have certain features that suggest a lower chance of recurrence.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Duarte, CaliforniaAges 18 years+ - NCT06756932RecruitingPhase 1
Bcl-2 inhibitor combo for advanced HR+ breast cancer
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
Iowa City, IowaAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Jonesboro, ArkansasAges 18 years+ - NCT06744465Recruiting
Light-based monitoring for breast cancer during chemo
This study uses a special light-based device to monitor breast cancer during chemotherapy before surgery. It is for women with HER2-positive or triple-negative breast cancer who are planning chemotherapy first.
Indianapolis, IndianaAges 18 years+ - NCT06358625Recruiting
Study of brain recurrence risk in HER2-positive breast cancer
This study looks at women with HER2-positive breast cancer who will get chemotherapy before surgery. The goal is to find out what factors might increase the chance of the cancer spreading to the brain later on.
RennesAges 18 years+ - NCT06732336RecruitingPhase 1/Phase 2
PET scan for HER2-low breast cancer
This trial uses a special PET scan to see if your breast cancer has low levels of a protein called HER2. This could help doctors choose the right treatment for you.
Sherbrooke, QuebecAges 18 years+ - NCT06731140RecruitingPhase 2
Reversing immune resistance in HER2-negative breast cancer
This trial tests a new treatment to see if it can reverse resistance to immunotherapy in people with HER2-negative breast cancer. It's for patients whose cancer has gotten worse after immunotherapy.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06727227Recruiting
Study of Enhertu for HER2-low breast cancer
This study looks at how well the drug Enhertu works for patients with HER2-low breast cancer that has spread. If you are already planning to start Enhertu, researchers will collect data from your regular care to learn more about its effectiveness.
Panagyurishte, PazardzhikAges 18 years+ - NCT06718010Recruiting
Blood markers and breast cancer treatment results
This study looks at how age-related changes in your blood might affect how well your breast cancer treatment works. It includes people with hormone receptor-positive, HER2-negative breast cancer that has not spread to distant organs.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06723990Recruiting
HER2 breast cancer treatment decision study
This study tests a tool called HER2DX to help doctors choose the best treatment for early stage HER2 positive breast cancer. It may help tailor therapy before or after surgery.
Milan, ItalyAges 18 years+ - NCT06706557Recruiting
Studying tumor DNA in HER2-low advanced breast cancer
This trial looks at tumor DNA in the blood of people with a certain type of advanced breast cancer called HER2-low. The goal is to learn more about this cancer and how it changes over time, which may help guide future treatments.
Milan, MIAges 18 years+ - NCT06695845RecruitingPhase 2
Study of zanidatamab for HER2-positive solid tumors
This trial tests a drug called zanidatamab in people with advanced solid tumors that have high levels of HER2 protein (called HER2-positive). It aims to see if zanidatamab can shrink or slow the growth of these tumors.
Prescott, ArizonaAges 18 years+ - NCT03740893RecruitingPhase 2
Test drug to block DNA damage in triple-negative breast cancer
This Phase 2 trial studies a treatment given around the time of breast surgery to help shrink or control residual (remaining) triple-negative breast cancer. It also checks biomarkers (lab signals) to understand who benefits, with some people receiving anti–PD-L1 immunotherapy and some not.
Bournemouth, DorsetAges 18 years+ - NCT06686394RecruitingPhase 1/Phase 2
Patritumab deruxtecan combinations for advanced HER2-positive breast cancer
This trial tests a new drug, patritumab deruxtecan, combined with other anti-cancer drugs for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. It aims to see if these combinations can shrink tumors or slow cancer growth.
Aurora, ColoradoAges 18 years+
Hear when a new HER2 + Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for her2 + breast cancer?
- Yes. Clin2 currently lists 952 recruiting her2 + breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a her2 + breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a her2 + breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.